Banerjee M, Findley L
Department of Neurology, Oldchurch Hospital, Essex, England, UK.
Cephalalgia. 1991 Sep;11(4):193-6. doi: 10.1046/j.1468-2982.1991.1104193.x.
The efficacy of the beta-adrenoceptor antagonist propranolol in the acute treatment of patients in attacks of either classical (migraine with aura) or common migraine (migraine without aura) headache was assessed in a double-blind placebo-controlled crossover trial with fixed doses. The trial was carried out on 25 patients. The treatment period was set at eight weeks, with the provision of shortening or lengthening it if necessary with a maximum period of seventeen weeks. A minimum of three migraine attacks were treated during each treatment period. Patients were assessed according to: the mean duration and mean severity per treatment period of migraine attacks. The secondary efficacy assessment was made on the basis of the percentage of attacks requiring escape medication per treatment period. The study, based on the t-distribution statistical model with a confidence level of 95%, showed that propranolol had no significant effect in aborting acute attacks of migraine when compared with placebo.
在一项采用固定剂量的双盲安慰剂对照交叉试验中，评估了β-肾上腺素能受体拮抗剂普萘洛尔对典型偏头痛（伴有先兆偏头痛）或普通偏头痛（无先兆偏头痛）发作患者进行急性治疗的疗效。该试验在25名患者身上进行。治疗期设定为8周，必要时可缩短或延长，最长为17周。每个治疗期至少治疗3次偏头痛发作。根据每个治疗期偏头痛发作的平均持续时间和平均严重程度对患者进行评估。次要疗效评估基于每个治疗期需要使用解救药物的发作百分比。该研究基于置信水平为95%的t分布统计模型，结果显示，与安慰剂相比，普萘洛尔在中止偏头痛急性发作方面没有显著效果。
